Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study

BACKGROUND. Immune-checkpoint-inhibitors (ICIs) have dramatically improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations. However, ICIs can also cause severe or even fatal immune-mediated adverse-events (irAE). Here, we ident...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Salem, Joe-Elie, Manouchehri, Ali, Moey, Melissa, Lebrun-Vignes, Bénédicte, Bastarache, Lisa, Pariente, Antoine, Gobert, Aurélien, Spano, Jean-Philippe, Balko, Justin M., Bonaca, Marc P., Roden, Dan M., Johnson, Douglas B., Moslehi, Javid J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287923/
https://ncbi.nlm.nih.gov/pubmed/30442497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30608-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados